Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy For Potential First-In-Class Cancer Drug
Portfolio Pulse from Benzinga Newsdesk
Certara, Inc. (NASDAQ:CERT) collaborated with Ichnos Glenmark Innovation to optimize the dosing strategy for ISB 2001, a potential first-in-class cancer drug. The collaboration focused on first-in-human dose prediction using Certara's virtual clinical trial platform, enhancing patient safety and efficacy.
September 18, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Certara's collaboration with Ichnos Glenmark Innovation on ISB 2001 highlights its expertise in model-informed drug development, potentially boosting its reputation and demand for its services.
Certara's involvement in optimizing the dosing strategy for a promising cancer drug candidate showcases its capabilities in model-informed drug development. This could lead to increased demand for its services, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80